Core Insights - Worthington Enterprises Inc. reported strong fourth quarter results for fiscal 2025, showing year-over-year and sequential growth in adjusted EBITDA, adjusted EPS, and free cash flow, driven by effective cost management and execution in its Consumer and Building Products segments [3][4][6]. Financial Performance - Net sales for Q4 2025 were $317.9 million, a slight decrease of 0.3% compared to Q4 2024, primarily due to the deconsolidation of the Sustainable Energy Solutions segment [5][6][8]. - The operating loss improved to $30.4 million from $56.1 million in the prior year, with adjusted operating income rising to $21.8 million, an increase of $16.0 million [5][9]. - Net earnings from continuing operations increased by 111% to $3.6 million, with adjusted EBITDA growing 35% to $85.1 million [6][9]. - Earnings per share from continuing operations improved from a loss of $(0.64) to a profit of $0.08, while adjusted EPS rose from $0.74 to $1.06 [6][28]. Cash Flow and Capital Management - Operating cash flow increased by 38% to $62.4 million, and free cash flow rose by 46% to $49.3 million [6][12]. - The company repurchased 200,000 shares for $9.8 million and declared a quarterly dividend of $0.19 per share, a 12% increase from the previous quarter [6][12]. Segment Performance - Consumer Products segment generated net sales of $125.6 million, remaining flat year-over-year, while adjusted EBITDA increased by $3.7 million to $20.8 million [14]. - Building Products segment saw net sales rise by 25.2% to $192.3 million, with adjusted EBITDA increasing by $19.6 million to $71.3 million, driven by higher volumes and contributions from the Ragasco acquisition [15][18]. Strategic Developments - The acquisition of Elgen Manufacturing for approximately $93 million was completed on June 19, 2025, aligning with the company's growth strategy in niche markets [6][16]. - The company expressed confidence in its ability to drive sustainable growth and long-term value heading into fiscal 2026 [16].

Elgen Manufacturing Worthington Enterprises acquires Elgen Manufacturing. COLUMBUS, Ohio, June 19, 2025 (GLOBE NEWSWIRE) -- Worthington Enterprises (NYSE: WOR), a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences, today announced its acquisition of Elgen Manufacturing (Elgen) of Closter, New Jersey. Elgen is a market-leading designer and manufacturer of HVAC parts and components, ductwork and structural framing primarily used in commercial ...

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 减少软组织损伤，是骨科手术中一个长期存在但始终未被结构性解决的问题。 2025年5月27日，芬兰初创医疗器械公司 Surgify Medical 宣布完成700万欧元（约合5716万人民币）A轮融 资 ，由 ZEISS Ventures 领投，欧洲创新委员会基金（EIC Fund）、Lednil 与 Cascara Ventures 跟投。 公司核心产品 Surgify Halo™ 是一款具备软组织保护机制的骨切割系统 ，已获得欧盟MDR和美国FDA认证， 并在北欧和德国完成超过 1000例 临床应用。 融资完成后，Surgify 将加快进入欧美市场的步伐，目标是成为新一代颅脑、脊柱等高风险术式中的骨钻替代 方案。 # 骨钻能否"认得"软组织？ 在颅脑或脊柱手术中，医生需要在靠近脑膜、血管、神经等关键结构的位置进行骨切操作。传统高速骨钻每分 钟转速高达几万转，稍有偏差就可能造成 ...

HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company’s growing body of clinical evidence, including collaborations with leading institut ...

HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipeline, support ...

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™. This significa ...